Shares of Valneva SE Sponsored ADR (NASDAQ:VALN – Get Free Report) traded down 5.6% during trading on Monday . Weiss Ratings reiterated a “sell (d-)” rating on shares of Valneva in a research note on Wednesday, October 8th. Three analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, Valneva presently has an average rating of “Moderate Buy” and an average target price of $15.00. Valneva Company Profile(Get Free Report)Valneva SE is a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases.